Seres Therapeutics Company Profile (NASDAQ:MCRB)

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Seres Therapeutics, Inc. (NASDAQ:MCRB) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by $0.10. The company earned $3 million during the quarter, compared to analysts' expectations of $3 million. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The business's quarterly revenue was up .0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.70) EPS. View Seres Therapeutics' Earnings History.

5 analysts have issued 1 year price objectives for Seres Therapeutics' shares. Their predictions range from $16.00 to $20.00. On average, they expect Seres Therapeutics' share price to reach $18.25 in the next year. View Analyst Ratings for Seres Therapeutics.

Here are some recent quotes from research analysts about Seres Therapeutics stock:

• 1. According to Zacks Investment Research, "Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (8/8/2017)
• 2. Cowen and Company analysts commented, "We are optimistic that modifications to the clinical trial plan for SER-109 in recurrent." (5/19/2017)
• 3. Canaccord Genuity analysts commented, "We believe that SER-109 Phase 2 trial study power was decreased by the inclusion of misdiagnosed and non-disease active patients. MCRB indicated that 72 of the 89 patients enrolled in the Phase 2 trials were chosen based on C. Difficile PCR diagnosis. A positive PCR test indicates that the cytotoxin gene is present, but does not directly indicate that the C. Difficile bacterium is producing the cytotoxin that causes the underlying symptoms. Thus a direct testing of cytotoxin is the most indicative of disease activity, and further qualifying stool samples analysis showed that only 15 of 31 PCR- positive samples were cytotoxin-positive. Importantly, Optimer utilized toxin testing for its fidaxomicin clinical program for recurrent C." (1/31/2017)

Some companies that are related to Seres Therapeutics include NeuroDerm (NDRM), Omeros Corporation (OMER), Xencor (XNCR), Acorda Therapeutics (ACOR), Dermira (DERM), Dynavax Technologies Corporation (DVAX), Sangamo Therapeutics (SGMO), Ascendis Pharma A/S (ASND), Retrophin (RTRX), Aduro Biotech (ADRO), Amarin Corporation PLC (AMRN), Keryx Biopharmaceuticals (KERX), Five Prime Therapeutics (FPRX), ZIOPHARM Oncology (ZIOP), Epizyme (EPZM), Insmed (INSM), PTC Therapeutics (PTCT) and Achaogen (AKAO).

Seres Therapeutics' management team includes the folowing people:

• Roger Pomerantz M.D., Chairman of the Board, President, Chief Executive Officer
• Eric D. Shaff, Chief Financial Officer, Executive Vice President
• John G. Aunins Ph.D., Chief Technology Officer, Executive Vice President - Bioprocess and Manufacturing
• David N. Cook Ph.D., Chief Scientific Officer, Executive Vice President - Research & Development
• Thomas J. DesRosier J.D., Chief Legal Officer, Executive Vice President and Secretary
• Michele Trucksis Ph.D. M.D., Chief Medical Officer and Executive Vice President
• Noubar B. Afeyan, Lead Independent Director
• Willard H. Dere M.D., Director
• Dennis A. Ausiello M.D., Independent Director
• Gregory Behar, Independent Director

(MCRB) raised $101 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Seres Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Flagship Pioneering Inc. (31.40%), FMR LLC (14.99%), Vanguard Group Inc. (3.92%), Capital World Investors (3.85%), ARK Investment Management LLC (1.89%) and Federated Investors Inc. PA (1.85%). Company insiders that own Seres Therapeutics stock include David N Cook, Eric D Shaff, John G Aunins, Michele Trucksis, Roger Pomerantz and Ventures Fund 2007 L Flagship. View Institutional Ownership Trends for Seres Therapeutics.

Seres Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., TIAA CREF Investment Management LLC, Federated Investors Inc. PA, Tudor Investment Corp ET AL, Goldman Sachs Group Inc., Wells Fargo & Company MN, Cutler Group LP and PDT Partners LLC. View Insider Buying and Selling for Seres Therapeutics.

Seres Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, State Street Corp, Northern Trust Corp, DekaBank Deutsche Girozentrale, Citadel Advisors LLC, Vanguard Group Inc., State of Wisconsin Investment Board and Dimensional Fund Advisors LP. View Insider Buying and Selling for Seres Therapeutics.

Shares of Seres Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Seres Therapeutics stock can currently be purchased for approximately $13.50.